Investing in Better Health Outcomes for Patients and Society
Anna Biosciences is a drug discovery company that uses decentralized partnerships to develop and advance new therapies for better patient outcomes.
Syntem Platform Team
Anthony Rullo, Ph.D.
Assistant Professor of Medicine at McMaster University
Anthony Rullo, Ph.D, is an Assistant Professor of Medicine at McMaster University where he has pioneered small molecule “proximity-inducing” therapeutic strategies with applications in immuno-oncology and anti-viral immunotherapeutics. → More
Laurence Unger, MBA
Laurence is an experienced executive and investment professional with a diverse background in hedge fund management, start-up and business development, and not-for-profit management. → More
Targeting COVID-19 and cancer with immunotherapy advancements 2 Sep 2021
Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform.
Press Release — Anna Biosciences Launches Pioneering Immunotherapeutic Treatment to Fight COVID-19 22 Jun 2021
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem.